VRE infections:  600 mg oral/IV q12h x 14-28 days.

Nosocomial pneumonia, complicated skin and skin structure infections, community-acquired pneumonia including concurrent bacteremia:  600 mg q12h x 10-14 days.

Uncomplicated skin and skin structure infections:  400 mg orally q12h x 10-14 days.

Renal: no adjustment necessary.
(Two primary metabolites of linezolid may accumulate in patients with renal insufficiency- more studies are needed to determine the clinical significance)